European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase 3 KEYNOTE-426 [...]
Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer
A recent study, published in Clinical Genitourinary Cancer reports a [...]
Low PD-L1 associated with long term response to sunitinib
Researchers from France have conducted a study to show that [...]
SMC approves nivolumab plus ipilimumab combination for advanced RCC
We are delighted to announce that the Scottish Medicines Consortium [...]
ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study
Results from the biomarker analysis from the JAVALIN Renal 101 [...]
Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
Results from this phase III trial of atezolizumab plus bevacizumab [...]
A review of adjuvant therapy options for kidney cancer
In this paper, published in Current Treatment Options in Oncology [...]
Predictive biomarkers in metastatic kidney cancer
A review published in European Urology Focus looks at tools [...]
Targeted therapies with immunotherapies in kidney cancer
The following video is an interview with Professor Thomas Powles [...]
Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
